Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 9Withdrawn 1Unknown 1Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 48Lymphoid 11Other hematologic neoplasm 7Thoracic 3Genitourinary 3CNS 3Sarcoma 1Other 1Myeloid 1Gastrointestinal 1Dermatologic 1

Conditions

Wilms Tumor 1Sarcoma 1Osteosarcoma 1Neoplasms 1Lymphoma 1Brain Neoplasms 1

Interventions

Cyclophosphamide 9Radiotherapy 8Temozolomide 6Magnetic Resonance Spectroscopy 6Filgrastim 6Doxorubicin 6pazopanib 5Gemcitabine 5pembrolizumab 4Vincristine 4Radiation 4Etoposide 4Docetaxel 4Carboplatin 4Biopsy 4Trabectedin 3Taxes 3Specimen Handling 3Paclitaxel 3Nivolumab 3Irinotecan 3Drug Therapy 3olaparib 2niraparib 2liposomal doxorubicin 2fludarabine phosphate 2fludarabine 2brigimadlin 2Trastuzumab 2Surgical Procedures, Operative 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Dexamethasone × Sarcoma × Clear all
NCT01236586 2017-07-02

RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 1 Withdrawn
CNSGenitourinaryLymphoidSarcoma

Brain Neoplasms, Lymphoma, Neoplasms, Wilms Tumor, Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡